NewLink Genetics Corporation (NLNK) : 12 days before expiry, shorts in NewLink Genetics Corporation (NLNK) have reduced from 3,178,733 on Jul 29, 2016, to 2,957,861 on August 15, 2016. On an average, 239,212 shares are traded on the exchange. The outstanding bearish positions are equal to 13.9% of the float. Short sellers have covered -220,872 shares, a reduction of -7%, which underlines that they dont expect the stock to fall further from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.
NewLink Genetics Corporation (NASDAQ:NLNK): The stock opened at $10.28 on Wednesday but the bulls could not build on the opening and the stock topped out at $10.78 for the day. The stock traded down to $9.90 during the day, due to lack of any buying support eventually closed down at $9.99 with a loss of -2.63% for the day. The stock had closed at $10.26 on the previous day. The total traded volume was 366,780 shares.
In a related news, Talarico Ernest Iii, director of Newlink Genetics Corp, executed a transaction worth $50,081 on June 6, 2016. A total of 4,065 shares were purchased at an average price of $12.32. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
NewLink Genetics Corporation (NewLink) is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes both biologic and small-molecule immunotherapy product candidates. Its biologic product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. Its small-molecule product candidates are focused on breaking the immune systems tolerance to cancer by inhibiting the indoleamine-(2, 3)-dioxygenase (IDO) pathway. Its lead product candidate algenpantucel-L or HyperAcute Pancreas. HyperAcute Pancreas is being studied in two Phase III clinical trials; one in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA) with the United States Food and Drug Administration (FDA) and one in patients with locally advanced pancreatic cancer.